Incyte (INCY) Cash from Operations (2010 - 2026)
Incyte's (INCY) quarterly Cash from Operations came in at 507662000.0 in Q2 2026, up 1034.67% YoY from 44741000.0 in Q2 2025, and up 37.45% on a QoQ basis from 369351000.0 in Q1 2026.
Analysis
Incyte (INCY) Cash from Operations (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Cash from Operations data on file, last reported at 507662000.0 in Q2 2026.
- Quarterly Cash from Operations rose 1034.67% year-over-year to 507662000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1979703000.0 (up 97.4% YoY) and the FY2025 annual result came in at 1413498000.0, up 321.52% from the prior year.
- Cash from Operations climbed to 507662000.0 in Q2 2026, from 369351000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 559389000.0 in Q3 2025 to a low of 575563000.0 in Q2 2024.
- A 5-year average of 227348666.67 and a median of 274864500.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 287.77% — and 2026, when it soared 1034.67%.
- Tracing INCY's Cash from Operations over 5 years: stood at 283662000.0 in 2022, then slumped by 47.92% to 147729000.0 in 2023, then surged by 158.05% to 381218000.0 in 2024, then surged by 42.52% to 543301000.0 in 2025, then dropped by 6.56% to 507662000.0 in 2026.
- The last three Cash from Operations figures came in at 507662000.0 (Q2 2026), 369351000.0 (Q1 2026), and 543301000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | 507.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 507.66 Mn |
| Mar 31, 2026 | 369.35 Mn |
| Dec 31, 2025 | 543.30 Mn |
| Sep 30, 2025 | 559.39 Mn |
| Jun 30, 2025 | 44.74 Mn |
| Mar 31, 2025 | 266.07 Mn |
| Dec 31, 2024 | 381.22 Mn |
| Sep 30, 2024 | 310.87 Mn |
| Jun 30, 2024 | -575.56 Mn |
| Mar 31, 2024 | 218.81 Mn |
| Dec 31, 2023 | 147.73 Mn |
| Sep 30, 2023 | 147.84 Mn |
| Jun 30, 2023 | 306.53 Mn |
| Mar 31, 2023 | -105.60 Mn |
| Dec 31, 2022 | 283.66 Mn |
| Sep 30, 2022 | 296.38 Mn |
| Jun 30, 2022 | 174.16 Mn |
| Mar 31, 2022 | 215.74 Mn |
| Dec 31, 2021 | 115.35 Mn |
| Sep 30, 2021 | 255.10 Mn |